Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: A Systematic Review and Meta-Analysis

Jianglei Ma  
Second Military Medical University

Xiaoyao Li  
Second Military Medical University

Shifu Zhao  
Second Military Medical University

Ruifu Zhang  
Second Military Medical University

Dejun Yang (✉ yangdejun@smmu.edu.cn)  
Shanghai Changzheng Hospital

Keywords: Robotic, Laparoscopic, Gastrectomy, Gastric cancer, Meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-84003/v1

License: ☟ ① This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background To date, robotic surgery has been widely used worldwide. We conducted a systematic review and meta-analysis to evaluate short- and long-term outcomes of robotic gastrectomy (RG) in gastric cancer patients to determine whether RG can replace laparoscopic gastrectomy (LG).

Methods Pubmed, Cochrane Library, WanFang, China National Knowledge Infrastructure (CNKI) and VIP databases were comprehensively searched for studies published before May 2020 that compared RG with LG. Next, two independent reviewers conducted literature screening and data extraction. The quality of the literature was assessed using the Newcastle-Ottawa Scale (NOS), and the data analyzed using the Review Manager 5.3 software. Random effects or fixed effects models were applied according to heterogeneity.

Results A total of 19 studies including 7275 patients were included in the meta-analyses, of which 4598 patients were in the LG group and 2677 in the RG group. Compared with LG, RG was associated with longer operative time (WMD=−32.96 min; 95% CI:−42.08~−23.84, P<0.00001), less blood loss (WMD=28.66 ml; 95% CI: 18.59~38.73, P<0.00001), and shorter time to first flatus (WMD=0.16 days; 95% CI: 0.06~0.27, P=0.003). There was no significant difference between RG and LG in terms of the hospital stay (WMD=0.23 days, 95% CI: −0.53~0.98, P=0.56), overall postoperative complication (OR=1.07, 95% CI: 0.91~1.25, P=0.43), mortality (OR=0.67, 95% CI: 0.24~1.90, P=0.45), the number of harvested lymph nodes (WMD=−0.96, 95% CI: −2.12~0.20, P=0.10), proximal resection margin (WMD=−0.10 cm, 95% CI: −0.29~0.09, P=0.30), and distal resection margin (WMD=0.15 cm, 95% CI: −0.21~0.52, P=0.41). No significant differences were found between the two treatments in overall survival (OS) (HR=0.95, 95% CI: 0.76~1.18; P=0.64), recurrence-free survival (RFS) (HR=0.91, 95% CI: 0.69~1.21; P=0.53), and recurrence rate (OR=0.90, 95% CI: 0.67~1.21; P=0.50).

Conclusions The results of this study suggested that RG is as acceptable as LG in terms of short-term and long-term outcomes. RG can be performed as effectively and safely as LG. Moreover, more randomized controlled trials comparing the two techniques with rigorous study designs are still essential to evaluate the value of the robotic surgery for gastric cancer.

Introduction

At present, gastric cancer is still a serious threat to human health and it is the third leading cause of cancer death and the fifth most commonly diagnosed cancer in the world [1]. Surgical resection is considered to be the gold standard of treatment for gastric cancer and open gastrectomy with lymphadenectomy took a dominant position in the treatment of gastric cancer. Since Kitano et al. [2] reported firstly LG for for gastric cancer in 1994, LG had been gradually spread worldwide.

Minimally invasive surgery (MIS) represents a new trend for its unique features. In recent years, LG has been recognized for its advantages of MIS in the treatment of gastric cancer, such as less blood loss, reduced invasiveness, less postoperative pain, early recovery of intestinal function, shorter hospital stay and less complication [3–9]. Clinical trials comparing laparoscopic with open surgery have shown that laparoscopic radical gastrectomy has the same long-term effects as open radical gastrectomy [10–12]. However, conventional laparoscopic surgery has also limitations of itself, including two-dimensional images, decreased sense of touch, amplification of hand tremor, lack of flexibility and limited ranges of
instrument movement. Besides, LG causes more physical stress and requires a long learning curve for surgeons, especially in lymph node dissection [13].

Recently, robot-assisted surgery, an emerging technology, has been used to overcome the technical drawbacks of conventional laparoscopic surgery. Advantages of robot-assisted surgery include high definition 3-D stereo video, convenient movements of the robotic arm, tremor suppression, and stable picture [14–16]. Application of the Da Vinci robotic surgical system has unlocked a new era of MIS, and it has been widely used in cardiovascular, urinary tract, hepatobiliary and gynecological surgery [17]. Since Hashizume et al. [18] reported the first RG in 2002, studies on RG have been widely reported.

Many studies have reported the safety and feasibility of RG, and are meaningful in highlighting the status of RG in the treatment of gastric cancer. However, these studies included small samples size, a single institution design and different appraise system of complications, which limited them to conclude objective result. Therefore, there is no clear conclusion whether RG can achieve an equal or even better surgical effect to LG. We conducted this systematic review and meta-analysis to explore and compare the clinical efficacy of RG and LG.

**Methods**

**Search Strategy**

A systematic literature search was performed in Pubmed, Cochrane Library, WanFang, CNKI and VIP for studies published before May 2020 that compared RG with LG, using the following searching terms: gastric cancer, gastric carcinoma, laparoscopic, robotic, and gastrectomy. In addition, the references of all relevant articles were also searched to find the additional literature. Only the studies in Chinese and English were included.

**Inclusion criteria and Exclusion criteria**

Included studies must meet the following criteria: (1) Clinical research comparing RG with LG for patients with gastric cancer; (2) Full-text article containing necessary data for statistical analysis, or including at least one of the following clinical outcomes: estimated blood loss, time to flatus, retrieved lymph nodes, operative time, length of hospital stay, proximal and distal margin distance, complications, and mortality; (3) If the same authors or center reported two or more studies, the most recent publication, the larger scale number publication or high quality publication were included. If 2 or more studies included totally different patients from the same center, we still analyzed the datum from those studies.

Articles were excluded if they included any of the following criteria: (1) Letters, review articles, conference reports, comments, case reports, and animal experimental studies; (2) Articles including non-gastric cancer cases such as gastrointestinal stromal tumors, or benign gastric diseases; (3) Articles without necessary data for statistical analysis.

**Data extraction and quality assessment of included studies**
Two authors independently and carefully reviewed and extracted the effective data from all included studies according to the inclusion and exclusion criteria, and checked the results again. If there was a disagreement, the controversial results were resolved by further discussion, and a final decision was made. The following data were collected from each study: first author, publication year, country, study design, sample size (RG group and LG group), age, body mass index (BMI), extent of resection, estimated blood loss (EBL), time to flatus, retrieved lymph nodes, operative time, length of hospital stay, proximal and distal margin distance, complications, mortality, OS, RFS and recurrence rate. If the research offered medians and ranges, the means and standard deviations (SDs) were estimated as described by Hozo et al. [19] The NOS was used to estimate the quality of included studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Scores range from 0 to 9 stars: studies with a score higher than or equal to 7 were considered to be high-quality and were included in the meta-analysis.

**Statistical analysis**

The meta-analysis was performed by using the Review Manager 5.3 software (Cochrane Collaboration, Oxford, UK). Continuous variables were assessed using weighted mean difference (WMD) and a 95% confidence interval (CI) and dichotomous variables using odds ratios (OR) with a 95% CI. The survival data, such as OS and RFS, were assessed using the hazard ratios (HR) and a 95% CI. The $I^2$ statistics was utilized to evaluate the heterogeneity. $I^2 < 25\%$, $25\% \leq I^2 \leq 50\%$ and $I^2 > 50\%$ were regarded as low, moderate and high heterogeneity. If the test of heterogeneity was high ($I^2 > 50\%$ or $P < 0.05$), a random-effect model was adopted. Otherwise, we used a fix effect model. Funnel plot was utilized to evaluate the potential publication of bias according to the overall complication. $P < 0.05$ was considered to be statistically significant.

**Results**

**Selected studies**

A total of 430 potential articles, which were published before May 2020, were retrieved from our databases. After removing 66 duplicates, 246 studies excluded by carefully reading the titles and abstracts because it was a review, letter, conference report, comment, case report or animal experimental study. 118 potential articles were thoroughly evaluated through full text articles, and finally, a total of 19 retrospective studies were included in the final meta-analysis according to inclusion and exclusion criteria [20–38]. A flow diagram of the search strategies, which includes reasons for the exclusion of studies, is shown in Fig. 1.

**Study characteristics and quality**

19 studies with a total of 7275 patients, of which 4598 patients were in the LG group and 2677 in the RG group, were involved. 14 of the included studies were published in English [22–29, 32–37], and 5 published in Chinese [20, 21, 30, 31, 38]. Among the 19 studies, 13 were from China [20–23, 28, 30–32, 34–38], 4 from Korea [24–26, 29] and 2 from Japan [27, 33]. The basic characteristics of the included studies are listed in Table 1. The evaluation of quality according to the NOS is shown in Table 2. NOS shows that 6 out of the 19
studies observed had 9 stars [23–25, 31, 33, 34], 2 had 8 stars [26, 32], and 11 had 7 stars [20–22, 17–30, 35–38].
| Study   | Year | Country | Design | Study Period | Group | Cases | Age   | BMI (kg/m²) | Surgical extension |
|---------|------|---------|--------|--------------|-------|-------|-------|-------------|-------------------|
| Zhang   | 2012 | China   | R      | 2009–2011    | RG    | 97    | 56.1 ± 5.8 | 22.5 ± 3.6 | D,P,T |
|         |      |         |  |              | LG    | 70    | 54.8 ± 4.9 | 21.7 ± 2.1 |       |
| Liu     | 2014 | China   | R      | 2012–2013    | RG    | 100   | 66.4 ± 5.7 | 22.7 ± 1.8 | D,P,T |
|         |      |         |  |              | LG    | 100   | 67.8 ± 4.8 | 23.1 ± 1.2 |       |
| Huang   | 2014 | China   | R      | 2008–2014    | RG    | 72    | 67.7 ± 15.1 | 24.1 ± 3.3 | D, T  |
|         |      |         |  |              | LG    | 73    | 66 ± 13.5  | 24.2 ± 3.3 |       |
| Zhou    | 2014 | China   | R      | 2010–2013    | RG    | 120   | 54.7 ± 10.1 | 21.6 ± 2.8 | D,P,T |
|         |      |         |  |              | LG    | 394   | 55.6 ± 11.8 | 21.7 ± 2.6 |       |
| Son T   | 2014 | Korea   | R      | 2003–2010    | RG    | 51    | 55.3 ± 12.2 | 22.7 ± 2.9 | T     |
|         |      |         |  |              | LG    | 58    | 58.8 ± 12.2 | 23.2 ± 3.3 |       |
| Han     | 2015 | Korea   | R      | 2008–2013    | RG    | 68    | 50.6 ± 8.3  | 22.7 ± 2.4 | PPG   |
|         |      |         |  |              | LG    | 68    | 49.8 ± 11.5 | 22.8 ± 3  |       |
| Lee     | 2015 | Korea   | R      | 2003–2010    | RG    | 133   | 53.6 ± 13.2 | 23.2 ± 2.7 | D     |
|         |      |         |  |              | LG    | 267   | 59.2 ± 11.7 | 23.7 ± 2.8 |       |
| Suda    | 2016 | Japan   | R      | 2009–2012    | RG    | 88    | 63.5 ± 15.0 | 22.6 ± 4.6 | D,T   |
|         |      |         |  |              | LG    | 438   | 64.0 ± 15.8 | 23.1 ± 6.4 |       |
| Shen    | 2016 | China   | R      | 2011–2014    | RG    | 93    | 56.8 ± 10.5 | 24.3 ± 3.3 | D,T   |

R, retrospectively collected data; D, distal gastrectomy; P, proximal gastrectomy; T, total gastrectomy; PPG, pylorus-preserving gastrectomy; BMI, body mass index; LG, laparoscopic gastrectomy; RG, robotic gastrectomy.
| Study  | Year  | Country | Design | Study Period | Group | Cases | Age       | BMI (kg/m²) | Surgical extension |
|--------|-------|---------|--------|--------------|-------|-------|-----------|-------------|-------------------|
| Hong   | 2016  | Korea   | R      | 2008–2015    | LG    | 330   | 57.9 ± 11.5 | 23.8 ± 3.6  | D,P               |
|        |       |         |        |              | LG    | 232   | 55.0 ± 13.0 | 23.8 ± 3.0  |                   |
| Lan    | 2017  | China   | R      | 2014–2016    | LG    | 673   | 59.0 ± 11.6 | 23.5 ± 4.5  | D,P,T             |
|        |       |         |        |              | LG    | 673   | 59.0 ± 11.6 | 23.5 ± 4.5  |                   |
| Zhang  | 2018  | China   | R      | 2011–2013    | LG    | 70    | 56.9 ± 12.1 | 23.6 ± 2.9  | D,P,T             |
|        |       |         |        |              | LG    | 70    | 56.9 ± 12.1 | 23.6 ± 2.9  |                   |
| Li     | 2018  | China   | R      | 2013–2017    | LG    | 112   | 56.1 ± 11.1 | 23.6 ± 3.0  | D,T               |
|        |       |         |        |              | LG    | 112   | 56.1 ± 11.1 | 23.6 ± 3.0  |                   |
| Obama  | 2018  | Japan   | R      | 2005–2009    | LG    | 311   | 54.8 ± 12.0 | 23.2 ± 2.8  | D,T               |
|        |       |         |        |              | LG    | 311   | 54.8 ± 12.0 | 23.2 ± 2.8  |                   |
| Gao    | 2019  | China   | R      | 2011–2014    | LG    | 163   | 59.88 ± 11.72 | 23.25 ± 3.26 | D,T               |
|        |       |         |        |              | LG    | 163   | 59.88 ± 11.72 | 23.25 ± 3.26 |                   |
| Sun    | 2019  | China   | R      | 2016–2018    | LG    | 88    | 54.7 ± 10.9 | 22.38 ± 3.03 | D,T               |
|        |       |         |        |              | LG    | 88    | 54.7 ± 10.9 | 22.38 ± 3.03 |                   |
| Ye     | 2020  | China   | R      | 2014–2019    | LG    | 285   | 57.1 ± 8.3  | 24.4 ± 2.3  | D                 |
|        |       |         |        |              | LG    | 285   | 57.0 ± 8.6  | 24.5 ± 2.2  |                   |
| Kong   | 2020  | China   | R      | 2014–2017    | LG    | 266   | 58.68 ± 10.54 | 24.23 ± 3.06 | D,P,T             |

R, retrospectively collected data; D, distal gastrectomy; P, proximal gastrectomy; T, total gastrectomy; PPG, pylorus-preserving gastrectomy; BMI, body mass index; LG, laparoscopic gastrectomy; RG, robotic gastrectomy.
| Study | Year | Country | Design | Study Period | Group | Cases | Age       | BMI (kg/m²) | Surgical extension |
|-------|------|---------|--------|--------------|-------|-------|-----------|-------------|-------------------|
| Cui   | 2020 | China   | R      | 2016–2019    | RG    | 187   | 59.0 ± 10.5 | 24.1 ± 3.0   | D                |
|       |      |         |        |              | LG    | 334   | 57.2 ± 11.9 | 23.8 ± 3.4   |                   |

R, retrospectively collected data; D, distal gastrectomy; P, proximal gastrectomy; T, total gastrectomy; PPG, pylorus-preserving gastrectomy; BMI, body mass index; LG, laparoscopic gastrectomy; RG, robotic gastrectomy.
| Study  | Selection (Out of 4) | Comparability (Out of 2) | Outcomes (Out of 3) | Total (Out of 9) |
|--------|----------------------|-------------------------|---------------------|-----------------|
|        |  (1)  (2)  (3)  (4) |                         |                     |                 |
| Zhang  | *     *     *     *  ** | *                       |                     | 7               |
| Liu    | *     *     *     *  ** | *                       |                     | 7               |
| Huang  | *     *     *     *  ** | *                       |                     | 7               |
| Zhou   | *     *     *     *  ** | *                       | *                   | 9               |
| Son T  | *     *     *     *  ** | *                       | *                   | 9               |
| Han    | *     *     *     *  ** | *                       | *                   | 9               |
| Lee    | *     *     *     *  *  | *                       | *                   | 8               |
| Suda   | *     *     *     *  *  | *                       | *                   | 7               |
| Shen   | *     *     *     *  ** | *                       |                     | 7               |
| Hong   | *     *     *     *  ** | *                       |                     | 7               |
| Lan    | *     *     *     *  ** | *                       |                     | 7               |
| Zhang  | *     *     *     *  ** | *                       | *                   | 9               |
| Li     | *     *     *     *  ** | *                       | *                   | 8               |
| Obama  | *     *     *     *  ** | *                       | *                   | 9               |
| Gao    | *     *     *     *  ** | *                       | *                   | 9               |
| Sun    | *     *     *     *  ** | *                       |                     | 7               |
| Ye     | *     *     *     *  ** | *                       |                     | 7               |
| Kong   | *     *     *     *  ** | *                       |                     | 7               |
| Cui    | *     *     *     *  ** | *                       |                     | 7               |

(1) Representativeness of the exposed cohort
(2) Selection of the non exposed cohort
(3) Ascertainment of exposure
(4) Demonstration that outcome of interest was not present at start of study
(5) Assessment of outcome
(6) Was follow-up long enough for outcomes to occur
(7) Adequacy of follow up of cohorts
Short-term outcomes

Figure 2, Fig. 3, Fig. 4 and Table 3 shows the results of meta-analysis for short-term and long-term outcomes. 18 studies reported the operative time. Because there was significant heterogeneity between 18 studies (I² = 94%, P < 0.00001), a random effect model was adopted. Meta-analysis revealed that the operative time was longer for RG than for LG (WMD = −32.96 min; 95% CI: 42.08−23.84, P < 0.00001) (Fig. 2a). The EBL was reported in 17 studies. Because of significant heterogeneity (I² = 81%, P < 0.00001), a random-effect model was used. The meta-analysis showed that the EBL was lower in RG than LG (WMD = 28.66 ml; 95% CI: 18.59−38.73, P < 0.00001) (Fig. 2b).

Pooled analysis showed that the number of days to first flatus of RG was shorter than LG, with a high heterogeneity (WMD = 0.16 days; 95% CI: 0.06−0.27, P = 0.003, I² = 65%) (Fig. 2c). All studies reported the days of hospital stay. A random-effect model was used because of significant heterogeneity (I² = 93%, P < 0.00001). The pooled results showed no difference in hospital stay between the RG and LG groups (WMD = 0.23 days, 95% CI: 0.53−0.98, P = 0.56) (Fig. 2d). All 19 studies present the overall postoperative complication. Analysis of the index revealed no significant difference between the groups of RG and LG (OR = 1.07, 95% CI: 0.91−1.25, P = 0.43) (Fig. 2e). The pooled result was measured using fixed-effects models due to the lack of significant heterogeneity (I² = 0%, P = 0.88). Moreover, 5 studies, with a total of 2148 gastric cancer patients, reported mortality. Pooled analysis showed no significant heterogeneity (I² = 0%, P = 0.82) using a fixed-effects model. Although no significant difference could be found in mortality between the two techniques, the pooled result revealed that LG group had a higher mortality than RG group (OR = 0.67, 95% CI: 0.24−1.90, P = 0.45) (Fig. 2f).

All of included studies reported the number of harvested lymph nodes. There was a significant heterogeneity, so a random effect model was adopted (I² = 83%, P < 0.00001). Analysis of the index revealed that harvested lymph nodes were similar between the groups of RG and LG (WMD = −0.96, 95% CI: −2.12−0.20, P = 0.10) (Fig. 3a). 7 studies reported the proximal margin and a fixed effect model was adopted because no significant heterogeneity was observed (I² = 28%, P = 0.22). The proximal margin was not significantly different between the two groups (WMD = −0.10 cm, 95% CI: −0.29−0.09, P = 0.30) (Fig. 3b). In terms of the distal margin, the difference between the two groups was not also significant (WMD = 0.15 cm, 95% CI: −0.21−0.52, P = 0.41), but the heterogeneity was significant (I² = 59%, P = 0.03) (Fig. 3c).

Long-term outcomes

The OS outcomes were recorded in 6 studies. Pooled analysis indicated no significant difference between the two techniques (HR = 0.95, 95% CI: 0.76−1.18, P = 0.64), and because of the lack of significant heterogeneity (I² = 0%, P = 0.86), a fixed effects model was used (Fig. 4a). The RFS outcomes were reported in 3 studies, which included a total of 1172 gastric cancer patients. The pooled results suggested that the RFS outcomes were similar between the RG and LG groups (HR = 0.91, 95% CI: 0.69−1.21, P = 0.53). The analysis had no obvious heterogeneity (I² = 0%, P = 0.91) using a fixed effects model (Fig. 4b). Five studies reported recurrence rates. The pooled results showed no significant difference in recurrence rate between the two groups (OR = 0.90, 95% CI: 0.67−1.21, P = 0.50), with no significant heterogeneity (I² = 0%, P = 0.62) (Fig. 4c).
Table 3
Results of the meta-analysis

| Outcomes                              | No. of studies | Sample size | Heterogeneity | Overall effect size | 95% CI of overall effect | P Value |
|---------------------------------------|----------------|-------------|---------------|---------------------|----------------------------|---------|
|                                       |                | LG          | RG            | I²(%)               | WMD                        |         |
| Operation time (min)                  | 18             | 3925        | 2481          | 94                  | -32.96                     | -42.08~23.84 | <0.00001 |
| Estimated blood loss (mL)             | 17             | 4196        | 2422          | 81                  | 28.66                      | 18.59~38.73 | <0.00001 |
| Retrieved lymph nodes                 | 19             | 4598        | 2677          | 83                  | -0.96                      | -2.12~0.20  | 0.10     |
| Proximal margin (cm)                  | 7              | 1252        | 761           | 28                  | -0.10                      | -0.29~0.09  | 0.30     |
| Distal margin (cm)                    | 6              | 1194        | 710           | 59                  | 0.15                       | -0.21~0.52  | 0.41     |
| Time to first flatus (days)           | 13             | 2847        | 1888          | 65                  | 0.16                       | 0.06~0.27   | 0.003    |
| Hospital stay (days)                  | 19             | 4598        | 2677          | 93                  | 0.23                       | -0.53~0.98  | 0.56     |
| Overall complications                 | 19             | 4598        | 2677          | 0                   | 1.07                       | 0.91~1.25   | 0.43     |
| Mortality                             | 5              | 1386        | 762           | 0                   | 0.67                       | 0.24~1.90   | 0.45     |
| Overall survival                      | 6              | 1498        | 890           | 0                   | 0.95                       | 0.76~1.18   | 0.64     |
| Recurrence-free survival              | 3              | 586         | 586           | 0                   | 0.91                       | 0.69~1.21   | 0.53     |
| Recurrence rate                       | 5              | 1038        | 757           | 0                   | 0.90                       | 0.67~1.21   | 0.50     |

Publication of bias

A funnel plot of overall complications was utilized to evaluate publication bias. The bilaterally symmetrical funnel plot of overall complications shown that no evidence of publication bias was found (Fig. 5).

Discussion

Radical gastrectomy with lymphadenectomy is regarded as gold standard of treatment for gastric cancer [39]. With the developing of minimally invasive techniques, MIS has gained a revolutionized application in gastrectomy. However, for gastric cancer, MIS experienced a controversy focusing on complication and mortality
for a long time. MIS increases quality of life, but it should be ensured that this technique does not increase complication and mortality, especially the new technique-RG [40]. Many studies have compared the safety and short or long term efficacy of LG with open gastrectomy [41–45], but studies on RG have not been sufficient to show the treatment's effectiveness. We included 19 studies and performed a meta-analysis to explore and compare the clinical efficacy of RG and LG.

The results of meta-analysis suggested that RG was associated with longer operative time, compared with LG. On one hand, the reason might come from time of setting and docking the robotic arms, which results in a longer operative time [46]. Studies had shown that it took about 30 minutes to prepare for robotic surgery [47]. On the other hand, the difference of surgeons’ experience might cause a longer operative time. Previous research reported that the operative time for RG decreased between the initial RG and gastrectomies performed after experience had been gained [48–50]. Woo et al. [51] reported 236 cases of robotic gastrectomy and found that the mean operative time was reduced from 233 to 219 min when compared with the previous 100 cases. Song et al. [52] described that after 25 initial learning cases, the time for docking and setting up the robotic arm was shortened and kept stable, about 15 minutes. Therefore, docking times can be shortened after accumulation of greater experience. In addition, the learning curve for RG can increase the operative time. With the development of the Da Vinci robotic surgery system, more experience, and a shortened learning curve, can make the robot surgery more and short time.

Blood loss during minimally invasive gastrectomy mainly occurs during lymph node collection and is caused by vascular damage. The meta-analysis indicated that the blood loss was lower in RG than in LG. The reason might be that robotic surgery has a high-definition visual field, eliminates hand tremors and accurately reveals the small structure around the stomach, which help surgeons better control bleeding in small blood vessels. Time to first flatus was a potential factor that should have an important impact on postoperative recovery. The results of meta-analysis suggested that there was significant difference in time to first flatus, and the time to first flatus was shorter in RG than in LG, which may be associated with minimal invasion and small stress response of RG [53]. However, the results of meta-analysis showed that the potential factor could not cause the different postoperative hospital stay between the groups of RG and LG. There was no statistical difference between the two groups on hospital stay, but it seemed to prefer the RG.

The postoperative complication rate is an important indicator of the short-term outcome. This meta-analysis indicated that the incidence of overall complications in the group of RG was less than in LG group, although no statistical difference. Regarding the mortality, analysis of the pooled data of the included studies suggested that mortality did not differ significantly between the two groups. According to these results, we believe that RG is safe and acceptable.

The result of tumor pathology is the key to evaluate the success of gastric cancer operation. This meta analysis revealed that there were no significant difference in proximal margin and distal margin between the two groups. Radical gastric cancer surgery requires extensive lymph node dissection, which helps to more accurately assess the patient's gastric cancer staging and prognosis. Regarding the number of harvested lymph nodes, analysis of the pooled data of the included studies revealed that the number of harvested lymph nodes in the group of RG was more than in LG group, although no statistical difference. The main reason is that RG has three-dimensional imaging, a tremor filter, and an internal articulated EndoWrist with 7° of freedom, which
contribute to precise dissection and lymphadenectomy, especially the lymph nodes of the soft tissue around the gastric vessels [17]. According to the standard of radical gastric cancer surgery, whether in the resection of the primary tumor or lymph node dissection, RG can achieve the goal of radical gastrectomy.

Because gastric cancer is a malignant tumor, the long-term follow-up oncological outcomes of gastric cancer patients were major concerns of surgeons. OS is a major oncologic outcome. In this meta analysis, the OS was similar to that previously reported [54]. The pooled data of the included studies revealed no significant difference between the RG and LG groups in OS, RFS, and the recurrence rate without heterogeneity. These results show that the two techniques have similar long-term oncologic outcomes. As far as we know, few meta-analysis had previously reported RFS with RG and LG. The RFS and recurrence rate results further demonstrated the comparability between RG and LG as far as long-term oncological outcomes in this meta analysis. These results confirmed that in terms of oncologic outcomes, RG is a safe technique for the management of gastric cancer.

When considering these results in clinical application, several limitations need to be taken into account. First, our meta-analysis included a large number of patients, but all studies included for analysis were retrospective studies, and none were randomized controlled trials, which influence the quality of meta-analysis and result in publication bias. However, no significant publication bias was shown in this meta-analysis. Second, some studies did not describe HRs and SEs directly. These data were extracted from the survival curves, which could cause a potential source of bias. Third, most of included studies were from East Asia East Asian countries, and the data regarding Western countries are limited. The generalizability and applicability of these results are limited. These results must be interpreted with caution. Finally, we found that the heterogeneities of operative time, blood loss, and number of retrieved lymph nodes were all significant. These parameters can be influenced by surgeons’ experience.

**Conclusion**

In conclusion, the results suggested that RG is as acceptable as LG in terms of short-term and long-term outcomes. Overall, our meta-analysis revealed that RG is an effective, safe and promising approach in treatment of gastric cancer, and make up for the defects of laparoscopy, which make patients have less trauma and quick recovery. More randomized clinical trials are still essential to further indicate the value of the robotic surgery for gastric cancer.

**List Of Abbreviations**

RG: robotic gastrectomy  
LG: laparoscopic gastrectomy  
CNKI: China national knowledge infrastructure  
NOS: Newcastle-Ottawa Scale  
OS: overall survival
Declarations

Ethics approval and consent to participate
The study did not need ethics approval.

Consent for publication
Not applicable

Availability of data and materials
The data in this manuscript are all provided in the tables and texts.

Competing interests
The authors declare that they have no competing interests.

Funding
This study was supported by the Natural Science Foundation of Shanghai (Grant No. 17ZR1439300); the Scientific Research Program of Shanghai Municipal Commission of Health and Family Planning (Grant No.
201640269); the National Natural Science Foundation of China (Grant No. 81772955).

Authors' contributions

JM and XL wrote the manuscript. SZ and RZ performed the data search and data analysis. DY performed the study design. All authors corrected and proofed the final text. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim, Yoon-Koo Kang. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. The Lancet Oncology 2018;19(10).

2. Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surgical Laparoscopy & Endoscopy 1994; 4(2):146-148.

3. Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surgical Endoscopy 2005;19(2):168-173.

4. Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Paola MD, Recher A, Ponzano C. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Annals of Surgery 2004;241(2):232-237.

5. Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surgical Endoscopy 2005;19(9):1172-1176.

6. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251(3):417–420.

7. Kodera Y, Fujiwara M, Ohashi N, Nakayama G, Koike M, Morita S, Nakao A. Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials. 2010;211(5):677–686.

8. Kitano S, Shiraishi N, Fujii K, Kazuhiro Yasuda. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002;131(1):S306-S311.

9. Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, Bae JM. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008;248(5):721—727.

10. Scatizzi M, Kröning KC, Lenzi E, Moraldi L, Cantafio S, Feroci F. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case–control study. Updates in Surgery, 2011, 63(1):17-23.
11. Kojima K, Yamada H, Inokuchi M, Hayashi M, Kawano T, Sugihara K. Current status and evaluation of laparoscopic surgery for gastric cancer. Nihon Geka Gakkai Zasshi 2010; 20(1):1-5.

12. Song J, Lee H J, Cho G S, Han SU, Kim MC, Ryu SW, Kim W, Song KY, Kim HH, Hyung WJ. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. Annals of Surgical Oncology 2010;17(7):1777-1786.

13. Kang SY, Lee SY, Kim CY, Yang DH. Comparison of Learning Curves and Clinical Outcomes between Laparoscopy-assisted Distal Gastrectomy and Open Distal Gastrectomy. Journal of Gastric Cancer 2010;10(4):247-253.

14. Toshiyasu O, Masaki N, Mikihiito N, Keiji H, Masahiro K, Junya K, Shimpei M, Toshio S, Hiroki Y. Robotic versus laparoscopic gastrectomy with lymph node dissection for gastric cancer: study protocol for a randomized controlled trial. Trials 2018;19(1):409-414.

15. Yang K, Cho M, Roh C K, Seo WJ, Choi S, Son T, Kim H, Hyung WJ. Robotic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. Surgical Endoscopy 2019;33:2357–2367.

16. Cianchi F, Indennitate G, Trallori G, Ortolani M, Paoli B, Macri G, Lami G, mallardi B, Badii B, Staderini F, Qirici E, Taddei A, Ringressi MN, Messerini L, Novelli L, Bagnoli S, Bonanomi A, Foppa C, Skalamera I, Fiorenza G, Perigli G. Robotic vs laparoscopic distal gastrectomy with D2 lymphadenectomy for gastric cancer: a retrospective comparative mono-institutional study. BMC Surgery 2016;16:65-70.

17. Liu GX, Shen WS, Chen L, Wei B. Robotic versus laparoscopic gastrectomy for gastric cancer: a meta-analysis. Zhong Hua Wei Chang Wai Ke Za Zhi 2016;19(003):328-333.

18. Hashizume M, Shimada M, Tomikawa M, Ikeda Y, Takahashi A, Koga F, Gotoh N, Konishi K, Maehara S, Sugimachi K. Early experiences of endoscopic procedures in general surgery assisted by a computer-enhanced surgical system. Surgical Endoscopy & Other Interventional Techniques 2002;16(8):1187-1191.

19. Hozo Stela Pudar, Djulbegovic Benjamin, Hozo Iztok. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 2005;5:13.

20. Zhang XL, Jiang ZW, Zhao K. Comparative study on clinical efficacy of robot-assisted and laparoscopic gastrectomy for gastric cancer. Zhong Hua Wei Chang Wai Ke Za Zhi 2012;15:804–808.

21. Liu J, Ruan H, Zhao K, Wang G, Li M, Jiang ZW. Comparative study on da Vinci robotic and laparoscopic radical gastrectomy for gastric cancer. Zhong Hua Wei Chang Wai Ke Za Zhi 2014;17:461–465.

22. Huang KH, Lan YT, Fang WL, Chen JH, Lo SS, Li AFY, Chiou SH, Wu CW, Shyr YM. Comparison of the Operative Outcomes and Learning Curves between Laparoscopic and Robotic Gastrectomy for Gastric Cancer. Plos One 2014;9.

23. Junfeng Zhou, Yan Shi, Bo Tang, Yingxue Hao, Dongzhu Zeng, Yongliang Zhao, Feng Qian, Peiwu Yu. Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: comparison of surgical performance and short-term outcomes. Surgical endoscopy 2014;28(6):1779-1787.

24. Son T, Lee JH, Kim YM, Kim HI, Noh SH, Hyung WJ. Robotic spleen-preserving total gastrectomy for gastric cancer: comparison with conventional laparoscopic procedure. Surgical Endoscopy 2014;28(9):2606-2615.

25. Han DS, Suh YS, Ahn HS, Kong SH, Lee HJ, Kim WH, Yang HK. Comparison of Surgical Outcomes of Robot-Assisted and Laparoscopy-Assisted Pylorus-Preserving Gastrectomy for Gastric Cancer: A Propensity Score Matching Analysis. Annals of Surgical Oncology 2015;22:2323–
26. Lee J, Kim YM, Woo Y, Obama K, Noh SH, Hyung WJ. Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy. Surgical endoscopy 2015;29(11):3251-3260.

27. Suda K, Man-M, Ishida Y, Kawamura Y, Satoh S, Uyama I. Potential advantages of robotic radical gastrectomy for gastric adenocarcinoma in comparison with conventional laparoscopic approach: a single institutional retrospective comparative cohort study. Surgical Endoscopy 2015;29(3):673-685.

28. Shen W, Xi H, Wei B, Cui J, Bian S, Zhang K, Wang N, Huang X, Chen L. Robotic versus laparoscopic gastrectomy for gastric cancer: comparison of short-term surgical outcomes. Surgical Endoscopy 2016;30(2):574-580.

29. Hong SS, Son SY, Shin HJ, Cui LH, Hur H, Han SU. Can Robotic Gastrectomy Surpass Laparoscopic Gastrectomy by Acquiring Long-Term Experience? A Propensity Score Analysis of a 7-Year Experience at a Single Institution. Journal of Gastric Cancer 2016;16(4).

30. Lan X, Xi HQ, Zhang KC, Cui JX, Li MS, Chen L. Comparison of complications following open, laparoscopic and robotic gastrectomy. Zhong Hua Wei Chang Wai Ke Za Zhi 2017;20(02):184-189.

31. Zhang K, Wei B, Xi HQ, Cui JX, Li ZY, Gao YH, Liang WQ, Hu C, Liu Y, Huang XH, Chen L. Comparison of the short-term and long-term outcome between robotic gastrectomy and laparoscopic gastrectomy: a propensity score matching analysis. Zhong Hua Wai Ke Za Zhi 2018;56(01):47-51.

32. Zhengyan L, Jipeng L, Bofei L, Bin B, Yezhou L, Bo L, Qingchuan Z. Robotic versus laparoscopic gastrectomy with D2 lymph node dissection for advanced gastric cancer: a propensity score-matched analysis. Cancer Management & Research 2018;Volume 10:705-714.

33. Obama K, Kim YM, Kang DR, Hyung WJ. Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer 2018;21:285–

34. Gao Y, Xi H, Qiao Z, Li J, Zhang K, Xie T, Shen W, Cui J, Wei B, Chen L. Comparison of robotic- and laparoscopic-assisted gastrectomy in advanced gastric cancer: updated short- and long-term results. Surg Endosc 2019;33: 528–

35. Sun LF, Liu K, Su XS, Wei X, Chen XL, Zhang WH, Chen XZ, Yang K, Zhou ZG, Hu JK, Silvestris N. Robot-Assisted versus Laparoscopic-Assisted Gastrectomy among Gastric Cancer Patients: A Retrospective Short-Term Analysis from a Single Institution in China. Gastroenterology research and practice 2019.

36. Ye SP, Shi J, Liu DN, Jiang QG, Lei X, Tang B, He PH, Zhu WQ, Tang HC, Li TY. Robotic- versus laparoscopic-assisted distal gastrectomy with D2 lymphadenectomy for advanced gastric cancer based on propensity score matching: short-term outcomes at a high-capacity center. Scientific reports 2020;10(1).

37. Ying Kong; Shougen Cao; Xiaodong Liu; Zequn Li; Liankai Wang; Cunlong Lu; Shuai Shen; Houxin Zhu; Yanbing Zhou. Short-Term Clinical Outcomes After Laparoscopic and Robotic Gastrectomy for Gastric Cancer: a Propensity Score Matching Analysis. Journal of Gastrointestinal Surgery Official Journal of the Society for Surgery of the Alimentary Tract 2020.

38. Cui H, Liu GX, Deng H, Cao B, Zhang W, Liang WQ, Xie TY, Zhang QP, Wang N, Chen L, Wei B. Comparison of short-term efficacy between robotic and 3D laparoscopic-assisted D2 radical distal gastrectomy for gastric cancer. Zhong Hua Wei Chang Wai Ke Za Zhi 2020; 23(4):350-356.
39. Wu HL, Tian Q, Peng CW, Liu SP, Li Y. Multivariate survival and outcome analysis of 154 patients with gastric cancer at a single Chinese institution. Asian Pacific Journal of Cancer Prevention 2011;12(12):3341-3345.

40. Zeng, YK, Yang ZL, Peng JS, Lin HS, Cai L. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Annals of Surgery 2012;256(1):39-52.

41. Best LM, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 2016;3(3):CD011389.

42. Katharina Beyer, Ann-Kathrin Baukloh, Carsten Kamphues, Hendrik Seeliger, Claus-Dieter Heidecke, Martin E. Kreis, Maciej Patrzyk. Laparoscopic versus open gastrectomy for locally advanced gastric cancer: a systematic review and meta-analysis of randomized controlled studies. World Journal of Surgical Oncology 2019.

43. Yao Wei, Deliang Yu, Yang Li, Chaogang Fan, Guoli Li. Laparoscopic versus open gastrectomy for advanced gastric cancer: A meta-analysis based on high-quality retrospective studies and clinical randomized trials. Clinics & Research in Hepatology & Gastroenterology 2018.

44. Inokuchi Mikito, Nakagawa Masatoshi, Tanioka Toshiro, Okuno Keisuke, Gokita Kentaro, Kojima Kazuyuki. Long- and short-term outcomes of laparoscopic gastrectomy versus open gastrectomy in patients with clinically and pathological locally advanced gastric cancer: a propensity-score matching analysis. Surgical Endoscopy 2018;32(2).

45. Hyung-Ho Kim; Sang-Uk Han; Min-Chan Kim; Wook Kim; Hyuk-Joon Lee; Seung Wan Ryu; Gyu Seok Cho; Chan Young Kim; Han-Kwang Yang; Do Joong Park; Kyo Young Song; Sang-II Lee; Seong Yeob Ryu; Joo-Ho Lee; Woo Jin Hyung. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KCLASS-01 Randomized Clinical Trial. JAMA oncology 2019;5(4).

46. Hu LD, Li XF, Wang XY, Guo TK. Robotic versus Laparoscopic Gastrectomy for Gastric Carcinoma: a Meta-Analysis of Efficacy and Safety. Asian Pacific Journal of Cancer Prevention 2016;17(9):4327-4333.

47. Kandil EH, Noureldine SI, Yao L, Slakey DP. Robotic Transaxillary Thyroidectomy: An Examination of the First One Hundred Cases. Journal of the American College of Surgeons 2012;214(4):558-564.

48. Hee KB, Yi X, Hoon H, Wook AC, Kwan CY, Han SU. Comparison of Surgical Outcomes between Robotic and Laparoscopic Gastrectomy for Gastric Cancer: The Learning Curve of Robotic Surgery. Journal of Gastric Cancer 2012;12(3):156-163.

49. Huang KH, Lan YT, Fang WL, Chen JH, Lo SS, Hsieh MC, Li AFY, Chiou SH, Wu CW. Initial experience of robotic gastrectomy and comparison with open and laparoscopic gastrectomy for gastric cancer. Journal of Gastrointestinal Surgery 2012;16(7):1303-1310.

50. Uyama I, Kanaya S, Ishida Y, Inaba K, Suda K, Satoh S. Novel Integrated Robotic Approach for Suprapancreatic D2 Nodal Dissection for Treating Gastric Cancer: Technique and Initial Experience. World Journal of Surgery 2012;36(2):331-337.

51. Woo Y, Hyung WJ, Pak KH, Inaba K, Obama K, Choi SH, Noh SH. Robotic gastrectomy as an oncologically sound alternative to laparoscopic resections for the treatment of early-stage gastric cancers. Arch Surg
52. Song J, Kang WH, Oh SJ, Hyung WJ, Choi SH, Noh SH. Role of robotic gastrectomy using da Vinci system compared with laparoscopic gastrectomy: initial experience of 20 consecutive cases. Surg Endosc 2009; 23:1204-1211.

53. Park JY, Jo MJ, Nam BH, B W Eom. Surgical stress after robot-assisted distal gastrectomy and its economic implications. British Journal of Surgery 2012; 99(11):1554-1561.

54. Liao G, Zhao Z, Khan M, Yuan Y, Li X. Comparative analysis of robotic gastrectomy and laparoscopic gastrectomy for gastric cancer in terms of their long-term oncological outcomes: a meta-analysis of 3410 gastric cancer patients. World Journal of Surgical Oncology 2019; 17(1).